After securing $7.6 million in its second round of Series A financing, which closed last week, Decision Biomarkers is getting ready to launch its first product: an automated system for evaluating up to 40 protein biomarkers for pharmaceutical customers.
Decision Biomarker claims that its flagship product is the first tool on the market that offers full automation for assaying biomarkers.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
